

***Monitoring of The Effect of Synthetic Vasopressin
in Vasodilatory Shock Using Esophageal Doppler Probe***

Thesis
**Submitted for Partial Fulfillment of
MD in Critical Care Medicine**

Investigator
Mohamed Ibrahim Afify
MB.B.Ch, MSch

Supervisors

Faheem Ragab MD.
Professor of Critical Care Medicine,
Critical Care Department -Cairo University

Hatem El Atroush MD.
Professor of Critical Care Medicine,
Critical Care Department -Cairo University

Nashwa Abed MD

***Asst. Prof. of Critical Care
Medicine,
Critical Care Department,
Cairo University***

Adel Hussein MD.

***Asst. Prof. of Critical Care Medicine,
Critical Care Department,
Cairo University***

Cairo University

2009

Abstract

Background: Septic shock is a form of vasodilatory shock characterized by arteriolar vasodilation the objective of treatment is to elevate tissue perfusion & mean arterial pressure to allow adequate organ perfusion. Noradrenaline and dopamine were the usual catecholamines used in the treatment of septic shock. Loss of response was the common problem that lead to patient loss after large continuous doses of noradrenaline which was termed as catecholamine refractory septic shock. Recently vasopressin and its analog namely terlipressin were used in the treatment of such catastrophic condition.

Methods and Results: In a prospective controlled study we included 40 patients with catecholamine resistant septic shock i.e. noradrenaline dose exceeded $0.6 \mu\text{g/kg/min}$ divided into two groups: 20 patients were treated conventionally according to surviving sepsis campaign 2008 who served as a control group and the other 20 patients were treated conventionally and when noradrenaline dose exceeded $0.6 \mu\text{g/kg/min}$ terlipressin in a dose of 1 mg I.V bolus every 12 hours for a study time of 48 hours was started. Terlipressin therapy was associated with increased MAP from 58 ± 14 mmHg at baseline to 73 ± 20 mmHg with P value: 0.008 after 48 hours that allowed significant reduction of noradrenaline dose from 50 mic/min on day 0 to $<25 \pm 8$ mic/min after 48 hours. Terlipressin therapy was associated with increased systemic vascular resistant from 546 ± 260 dyne.sec/cm⁻⁵ to 986 ± 390 dyne sec/cm⁻⁵ after 48 hour which represent normalized arteriolar tone that is expected to allow better organ bed perfusion.

There was reduction of both stroke volume and cardiac output (from 63 ± 16 ml/beat to 51ml/beat and from 78 liter/min to 5.3 litre/min, respectively) yet this was not associated with abnormal organ perfusion marked by improved urine output from 49 ml/hour to 133 ml/h and improved global perfusion as marked by improved base deficit which represent lactic acidosis from 9.3 ± 3 mEq/L to 5.7 ± 3 mEq/L P value: <0.002 . Terlipressin therapy was not associated with deleterious effect on PO_2/FiO_2 ratio (from 208 ± 74 to 211 ± 118 after 48 hours. Yet there was significant reduction of oxygen delivery (Do_2 from 848 ml/min to 610 ± 47 ml/min after 48 hours ($P > 0.02$).

There was no effect on length of ICU stay in both groups (16 ± 6 in the terlipressin group and 12 ± 6 days in control group, $P < 0.06$). This shorter length of stay in control group may be due to the rapid deterioration of hemodynamics and death without terlipressin support, shown true as mortality in control group of 70% versus 60% (12/20) in terlipressin group with absolute risk reduction of 10% and relative risk reduction of 25%. Regarding organ function, terlipressin could improve SOFA score from 11 ± 3.2 to 8 ± 5 with P value: <0.02 .

Conclusion: Terlipressin is a rather safe inexpensive easy to administer alternative in the treatment of septic shock. Further studies are needed to decide the ideal timing for initiation of this therapy early vs late, adjuvant or as an initial treatment.

Key words: Terlipressin, catecholamine resistant septic shock.

Table of Content

Item	Page
Introduction	1-2
Aim of Work	3
Review:	4-74
○ <i>Chapter I: Sepsis & Septic shock</i>	4-27
○ <i>Chapter II: MODS & Scoring systems</i>	28-42
○ <i>Chapter III: Esophageal Dopplex Monitoring a minimally invasive alternative</i>	43-61
○ <i>Chapter IV: Terlipressin in Septic Shock: When and how much?</i>	62-74
Patients & Methods	75-84
Results	85-113
Discussion	114-125
Summary	126-128
Conclusion	129
References	130
Arabic Summary	3-1

Acknowledgement

For ALLAH the merciful, the compassionate, I kneel to express my gratitude for all the countless gifts I have been offered, including those who gave their hands to enable me to fulfill this work.

*No words are sufficient to express my deep appreciation and profound gratitude to **Prof. Dr. Sherif Mokhtar**, Professor of Critical Care Medicine, and **Prof. Dr. Hassan Khaled**, Professor of Critical Care Medicine and Chief of Critical Care Medicine Department.*

*I am deeply thankful to **Prof. Dr. Faheem Ragab**, Professor of Critical Care Medicine and Director of Critical Care Center for his great help, outstanding support and active participation, and for his extreme patience and understanding.*

*My true appreciation is due to **Prof. Dr. Hatem El Atroush**, Professor of Critical Care Medicine, for his kind guidance, patience, valuable instructions, generous help and fruitful encouragement.*

*I would deeply like to thank **Prof. Dr. Nashwa Abed**, Asst. Prof. of Critical Care Medicine, for her meticulous supervision, her valuable instructions, generous help, her sincere efforts, support and her simplicity in handling matters.*

*I would also like to thank **Dr. Adel Hussein** Asst. Prof. of Critical Care Medicine for his help, support and his simplicity in handling matters.*

*I wish to thank deeply Mrs. **Manal Youssef**, Critical Care Medicine Department for her patience in performing the computer work of this thesis.*

Special thanks for all my colleagues in critical care department who helped me a lot to finish this work.

I am very thankful to all nursing staff for their great participation and meticulous performance.

*My all gratitude for my family and my wife **Dr.Samah Shehata** for their unlimited support.*

Finally I am so thankful and honored to belong to the critical care medicine department, the land of innovation and fruitful research.

Mohamed Ibrahim Afify

List Of Abbreviations

APACHE:	Acute Physiology and chronic healthy evaluation
CD:	Cluster Determinant
CO:	Cardiac output
CSA:	Cut sectional area
CVP:	Central venous pressure
DIC:	Disseminated intravascular coagulopathy
DNA:	Deoxyribonucleic acid
DO ₂ :	Oxygen delivery per minutes
ED:	Emergency Department
EDM:	Esophageal Doppler Monitoring
EGDT:	Early goal directed therapy
FiO ₂ :	Fractional of oxygen in inspired air
FTc:	Flow time corrected for heart rate
HLA:	Human leukocyte antigen
ICU:	Intensive care unit
IFN α :	Interferone Gamma
IL:	Interleukin
iNOS:	Nitric oxide synthase "inducible subtype"
MAP:	Mean arterial pressure
MD:	Minutes distance
nNOS:	Nitric oxide synthase "neuronal subtype"
NO:	Nitric oxide
PAC:	Pulmonary artery Catheter
PAOP:	Pulmonary artery occlusion pressure
PO ₂ :	Parametric pressure of oxygen
PV:	Peak velocity
SBP:	Systolic blood pressure
ScvO ₂ :	Central venous blood oxygen saturation
SD:	Standard deviation

SD:	Stroke Distance
SOFA:	Sequential organ failure score
SV:	Stroke volume
TF:	Tissue factor
TGF:	Transforming growth factor
TGF- β :	Transforming Growth factor β
Th:	T lymphocytes helper cells helper cells
TVI:	Time-velocity integral
VO ₂ :	Oxygen consumption
WBC:	White blood cells

List Of Tables

<i>Item</i>	<i>Page No.</i>
Table 1: showing SOFA scoring	39
Table 2: Correlation Data:	49
Table 3: Esophageal Doppler Monitor Parameters	53
Table 4. Clinical studies on bolus injection and case reports on continuous infusion of terlipressin in patients with septic shock.	71
Table 5: Mean Age of Group I & Group II	86
Table 6: Gender distribution in patients of both study group (group I, group II)	87
Table 7: Different risk factors of sepsis in (group I, group II)	87
Table 8: Source of sepsis in both groups	88
Table 9: Mean of APACHE II score in (group I & group II)	89
Table 10: SOFA score in both groups	90
Table 11: APACHE II score in survivors & non survivors	91
Table 12: SOFA score in survivors & non survivors	92
Table 13: Stroke volume in survivors & non survivors	93
Table 14: CO in survivors & non survivors	94
Table 16: SVR in survivors & non survivors	95
Table 17: Effect of terlipressin on SV (12 hours)	96
Table18: Effect of terlipressin on SV (24 hours)	96

<i>Item</i>	<i>Page No.</i>
Table 19: Effect of terlipressin on SV (36 hours)	97
Table 20: Effect of terlipressin SV (48 hours)	97
Table 21: Effect of terlipressin on CO	98
Table 22: Effect of terlipressin on SVR	99
Table 23: Effect of terlipressin on HR	100
Table 24: Effect of terlipressin on MAP	101
Table 25: Improvement of base deficit with terlipressin therapy	102
Table 26: Effect of terlipressin on UOP	103
Table 27: Correlation between Before ALT & after ALT	104
Table 28: Correlation between Before Bilirubin & after Bilirbulin	104
Table 29: Effect of terlipressin on (PO ₂ /FiO ₂) ratio	105
Table 30: Effect of terlipressin on DO ₂	106
Table 31: Effect of terlipressin in VO ₂	107
Table 32: Effect of terlipressin on weaning of noradrenaline	108
Table 33: Effect of terlipressin on LOS	109
Table 34: Effect of terlipressin on organ functions marked by improvement of SOFA score	110
Table 35: correlation between CO by EDP and TTE	111
Table 36. Clinical studies on bolus injection and case reports on continuous infusion of terlipressin in patients with septic shock.	121

List Of Figures

<i>Item</i>	<i>Page No.</i>
Fig 1: showing pro & anti- inflammatory responses after septic shock & onset of conventional therapy, advances in sepsis vol 4.	10
Fig 2: protocol for early goal directed therapy	22
Figure (3); Esophageal Doppler monitor. Used with permission from Deltex Medical, Inc. Severna Park, Md.	47
Figure (4): Esophageal Doppler monitors probe replacement. Used with permission from Deltex Medical, Inc., Severna Park, Md.	51
Figure (5): Esophageal Doppler monitors waveform. PV, Peak velocity; FTc, flowtime corrected; SD; stroke distance. Used with permission from deltex medical, inc., Severna park, Md.	51
Figure (6): Esophageal Doppler monitors waveform changes, used with permission of deltex medical, Inc., Severna Park, Md.	52
Figure (7): Challenges faced in interpreting pulmonary artery pressures. Left: PAOP = 20 mm Hg; normal left ventricle (LV) with high end-diastolic volume. Center: PAOP = 20 mm Hg; enlarged right ventricle (RV) with juxtacardiac pressure; end-diastolic volume. Right: PAOP = 20 mm Hg, hypertrophied noncompliant left ventricle with low end-diastolic volume. Used with Permission from Deltex Medical, Inc., Severna Park, Md.	54
Fig. (8): Chemical structure of terlipressin FP, N α -Triglycyl 8-lysine vasopressin). The ellipse labels the three glycyl residues.	64

<i>Item</i>	<i>Page No.</i>
Fig. (9): Signal transduction of terlipressin (IP). AMP: adenosine monophosphate; AQP2: aquaporin 2; AVP: arginine vasopressin; Ca ²⁺ : calcium; cAMP: cyclic adenosine triphosphate; DAG: diacyl glycerol; GDP: guanosyl diphosphate; GTP: guanosyl triphosphate; H ₂ O: water; IP ₃ : inositole trisphosphate; MLCK: myosin light chain kinase; PIP ₂ : phosphatidyl inositole bisphosphate; PKA: proteinkinase A; PLC: phospholipase C; V ₁ : V ₁ vasopressin receptor; V ₂ : V ₂ vasopressin receptor; VSMC: vascular smooth muscle cell.	66
Fig. (10): Position of pulmonary artery catheter pressure system	78
Fig. (11): Deletex Cardio Q esophageal Doppler monitor	79
Fig. (12): Probe “Reusable“	80
Fig. (13): Probe “Disposable“	80
Fig (14): Two dimensional echocardiography image in the parasternal long axis view to measure the left ventricular outflow tract diameter in patient number (12).	81
Fig (15): Pulsed-Doppler echocardiographic image in the apical four-chamber view to measure velocity time integral of the left ventricular outflow tract. Three consecutive cardiac cycles were analyzed and averaged.	81
Fig. (16): Equations used to calculate SV & CO	82
Fig. (17): Study design	83
Fig. (18): Age of both groups	87
Fig. (19): Risk factor of sepsis in both groups	88

<i>Item</i>	<i>Page No.</i>
Fig. (20): Source of sepsis in both groups	88
Fig. (21): APACHE II score in both groups	89
Fig. (22): SOFA score in both groups	90
Fig. (23): APACHE II score in survivors & non survivors	91
Fig. (24): SOFA score in survivor & non survivors	92
Fig. (25): Stroke volume in survivor & non survivors	93
Fig. (26): CO in survivors & non survivors	94
Fig. (27): SVR in survivors & non survivors	95
Fig. (28): Effect of terlipressin on SV (12 hours)	96
Fig (29): Effect of terlipressin on SV (24 hours)	96
Fig. (30): Effect of terlipressin on SV (36 hours)	97
Fig. (31): Effect of terlipressin SV (48 hours)	97
Fig. (32): Effect of terlipressin on CO	98
Fig. (33): Effect of terlipressin on SVR	99
Fig. (34): Effect of terlipressin on HR	100
Fig. (35): Effect of terlipressin on MAP	101
Fig. (36): Improvement of base deficit with terlipressin therapy	102
Fig. (37): Effect of terlipressin on UOP	103
Fig (38): Correlation between Before ALT & after ALT	104
Fig (39): Correlation between Before Bil. & after Bil	104
Fig. (40): Effect of terlipressin on (PO ₂ /FiO ₂) ratio	105
Fig. (41): Effect of terlipressin on DO ₂	106
Fig. (42): Effect of terlipressin in VO ₂	107

<i>Item</i>	<i>Page No.</i>
Fig. (43): Effect of terlipressin on weaning of noradrenaline	108
Fig. (44): Effect of terlipressin on LOS	109
Fig. (45): Effect of terlipressin on organ functions marked by improvement of SOFA score	110
Fig. (46): Correlation between CO measured by EDP & transthoracic echo	111
Fig. (47): Correlation between CO measured by EDP and PAC	112
Fig. (48): Complications of PAC in treatment group	113

Abbreviations of Master Table

BSA	Body surface area
MAP	Mean arterial pressure
0	Base line
1	12 hours
2	24 hours
3	36 hours
4	48 hours
HR	Heart rate
CVP	Central venous pressure in mmHg
UOP	Urine output in ml/hour
SOFA	Sequential organ failure score
COP-edp	Cardiac output measured by esophageal Doppler probe at day 0
SV	Stroke volume ml/beat
FTc	Flow time corrected for heart rate by m.sec
SVR	Systemic vascular resistance
Echo-Co	Cardiac output measured by transthoracic echo at day 0
NA	Noradrenaline dose in mic/min
PAC-CO	Cardiac output measured by pulmonary artery catheter in litre/min
FiO ₂	Fraction of oxygen in inspired air
DO ₂	Oxygen delivery in ml/min
VO ₂	Oxygen consumption in ml/min
ALT	Alamine transfrange
DM	Diabetes mellitus
LOS	Length of stay
0	No
1	yes

Introduction

- Endotoxic shock is a syndrome of cardiovascular collapse and multiple organ failure in response to bacterial products (*Parrillo et al., 1990*).
- The central characteristic of septic shock is systemic vasodilatation, the cause of which is multifactorial the most common cause is excessive nitric oxide synthesis and activation of vascular smooth muscle K⁺ ATP channel. *Kilbourn et al., 1990, Landry et al., 1992*.
- Vascular smooth muscle is poorly responsive to noradrenaline (NA) in septic shock *Meadow et al., 1988*, and vasopressin doesn't play a significant role in the control of vascular smooth muscle in normal conditions *Schwartz et al., 1981*, but becomes critical when blood pressure is threatened (*Schwartz et al., 1981*).
- Recent studies showed that some patients in advanced vasodilatory septic shock are exquisitely sensitive to the pressure effect of the exogenous vasopressin therapy.
- This unexpected finding raised the possibility that endogenous plasma vasopressin is inappropriately low in these patients.
- The most common theories for vasopressin deficiency is first, deficient baroreflex-mediated secretion of vasopressin i.e. primary autonomic failure *Kautmann et al., 1999* the second explanation is depletion of secretory stores of the neurohypophysis (*Jones CW et al., 1969, Cook et al., 1993*).

- The above findings are the new concept of treatment of catecholamine resistant septic shock by replacement of the deficient vasopressin in this group of patients.